Gilead Upgraded With Covid Sales Seen Reaching $7.7 Billion

(Bloomberg) -- A formerly cautious analyst at SVB Leerink has changed his tune on the potential sales of Gilead Sciences Inc.’s Covid-19 treatment, remdesivir.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.